Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

195.50 +4.30 (+2.25%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

57 58 Next >

Large Cap Biopharmaceuticals Performance ↗

May 20, 2024

The biotech sector remains a laggard YTD as can be seen by the IBB.

Via Talk Markets

Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024 ↗

May 17, 2024

With new innovation, millions of retiring baby boomers, and an increase in mergers, biotech stocks to buy have a good deal of upside ahead.

Via InvestorPlace

Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another ↗

May 16, 2024

Ionis Pharmaceuticals and Biogen have halted development of BIIB105 for ALS after Phase 1/2 study results showed no impact on key clinical outcomes.

Via Benzinga

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

May 16, 2024

From Biogen Inc.

Via GlobeNewswire

The Analyst Landscape: 27 Takes On Biogen ↗

April 29, 2024

Via Benzinga

Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week ↗

April 29, 2024

With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages.

Via Benzinga

Topics Stocks

Biogen Stock Continues Its 20% Sprint On A Twist In Alzheimer's Treatment ↗

May 15, 2024

The company is hoping to launch an under-the-skin version of its infusion, Leqembi.

Via Investor's Business Daily

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status

May 14, 2024

From Biogen Inc.

Via GlobeNewswire

Jim Cramer Likes Micron And Its CEO, Recommends Buying This Big Bank ↗

May 13, 2024

Jim Cramer recommends buying Micron, adding that he likes the company's CEO Sanjay Mehrotra. As for Fidelis? "Not a favorite."

Via Benzinga

3 S&P 500 Stocks to Rival Nvidia’s 2023 Performance in the Second Half of 2024 ↗

May 11, 2024

Let’s explore three stocks that are well-positioned to rival Nvidia’s growth rates in the second half of 2024.

Via InvestorPlace

Topics Stocks

These Analysts Revise Their Forecasts On Biogen After Q1 Results ↗

April 25, 2024

Via Benzinga

Where Biogen Stands With Analysts ↗

April 11, 2024

Via Benzinga

Looking Into Biogen's Recent Short Interest ↗

April 03, 2024

Via Benzinga

The 3 Most Undervalued Pharma Stocks to Buy in May 2024 ↗

May 09, 2024

Investors looking for good deals in the pharmaceutical industry should watch out for these three undervalued pharma stocks.

Via InvestorPlace

Why Is Nuvo Group (NUVO) Stock Up 200% Today? ↗

May 06, 2024

Although prenatal care specialist Nuvo Group saw its shares soar on Monday, NUVO stock faces skepticism over its SPAC merger.

Via InvestorPlace

Biogen Reports Progress on Corporate Responsibility Priorities

May 02, 2024

From Biogen Inc.

Via GlobeNewswire

7 Retirement Stocks to Buy at a 52-Week Low in April ↗

April 29, 2024

One of the best ways to keep your portfolio safe while generating income is with dividend-paying retirement stocks at 52-week lows.

Via InvestorPlace

Topics Retirement

Stock Market Rebounds; Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review ↗

April 26, 2024

Microsoft, Tesla, Google, GE and Chipotle were earnings winners. Meta was a notable loser.

Via Investor's Business Daily

Meta Platforms To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Thursday ↗

April 25, 2024

Via Benzinga

Why Biogen Stock Leaped Nearly 5% Higher Today ↗

April 24, 2024

The company came out swinging with its first set of quarterly earnings for this year.

Via The Motley Fool

Biogen/Eisai's Popular Alzheimer's Drug Leqembi Is Seeing Slow Adoption - Here's Why ↗

April 24, 2024

Discover the challenges facing Leqembi, the first Alzheimer's drug shown to slow progression. Skepticism among doctors and concerns about efficacy and costs hinder widespread adoption despite FDA...

Via Benzinga

Biogen (BIIB) Q1 2024 Earnings Call Transcript ↗

April 24, 2024

BIIB earnings call for the period ending March 31, 2024.

Via The Motley Fool

Topics Earnings

Biogen's Leqembi Commercial Ramp-Up Modest But Up Ticking, Reports Mixed Bag Q1 Earnings ↗

April 24, 2024

Biogen reports Q1 results: adjusted EPS $3.67 (beat consensus), sales $2.29 billion (missed consensus). Leqembi launch uptake triples, Zurzuvae's early trends encouraging.

Via Benzinga

Treasury Yields Rise, Tesla Jumps On Cheaper Model Pledge, Yen Plummets To 34-Year Lows: What's Driving Markets Wednesday? ↗

April 24, 2024

Rising Treasury yields have investors cautious despite positive news from the earnings season. The yield on the long-dated 30-year Treasury bond has surged to 4.79%. It’s on track to close at the...

Via Benzinga

Topics Bonds

BIIB Stock Earnings: Biogen Beats EPS, Misses Revenue for Q1 2024 ↗

April 24, 2024

BIIB stock results show that Biogen beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Via InvestorPlace

Two Notable Biogen Drugs Walloped Sales Forecasts. Will It Be Enough To Reverse Biogen Stock's Decline? ↗

April 24, 2024

Biogen shares have lost nearly 40% of their value since last June. Could two key sales beats help revive shares?

Via Investor's Business Daily

Topics Earnings

Nasdaq Futures Get A Lift From Tesla, Texas Instruments Earnings: Analyst Points To Key Catalyst For Boosting Rally ↗

April 24, 2024

Nasdaq and S&P 500 futures signaled a higher open on Wednesday, thanks to upbeat guidance from EV giant Tesla, Inc. (NASDAQ:TSLA) and semiconductor m

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

April 09, 2024

Via Benzinga

10 Big-Name Stocks Near 52 Week Lows: Are They A Buy? ↗

March 29, 2024

Over the past twelve months, a number of big-name companies have been near or below their 52-week low price. Each week we’ll take a look at some of the biggest names currently close to their 52-week...

Via Talk Markets

Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week ↗

April 21, 2024

Corporate profit growth rose in Q3 2023 and is expected to continue in Q1.

Via Benzinga

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

57 58 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Biogen Idec (NQ:BIIB)

All News about Biogen Idec

Starting at $3.75/week.

Subscribe Today